Literature DB >> 9586351

Fc receptors on natural killer cells.

B Perussia1.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 9586351     DOI： 10.1007/978-3-642-46859-9_6

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN： 0070-217X            Impact factor:   4.291


× No keyword cloud information.
  26 in total

1.  miR-155 regulates IFN-γ production in natural killer cells.

Authors:  Rossana Trotta; Li Chen; David Ciarlariello; Srirama Josyula; Charlene Mao; Stefan Costinean; Lianbo Yu; Jonathan P Butchar; Susheela Tridandapani; Carlo M Croce; Michael A Caligiuri
Journal:  Blood       Date:  2012-02-29       Impact factor: 22.113

2.  Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development.

Authors:  Aaron R Victor; Christoph Weigel; Steven D Scoville; Wing Keung Chan; Kelsey Chatman; Mary M Nemer; Charlene Mao; Karen A Young; Jianying Zhang; Jianhua Yu; Aharon G Freud; Christopher C Oakes; Michael A Caligiuri
Journal:  J Immunol       Date:  2017-12-11       Impact factor: 5.422

3.  The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells.

Authors:  Rossana Trotta; David Ciarlariello; Jessica Dal Col; Hsiaoyin Mao; Li Chen; Edward Briercheck; Jianhua Yu; Jianying Zhang; Danilo Perrotti; Michael A Caligiuri
Journal:  Blood       Date:  2010-12-14       Impact factor: 22.113

Review 4.  Activation, coactivation, and costimulation of resting human natural killer cells.

Authors:  Yenan T Bryceson; Michael E March; Hans-Gustaf Ljunggren; Eric O Long
Journal:  Immunol Rev       Date:  2006-12       Impact factor: 12.988

5.  Characterization of murine cytomegalovirus m157 from infected cells and identification of critical residues mediating recognition by the NK cell receptor Ly49H.

Authors:  Aja H Davis; Natalya V Guseva; Brianne L Ball; Jonathan W Heusel
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

6.  A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.

Authors:  Tanios S Bekaii-Saab; Julie M Roda; Kristan D Guenterberg; Bhuvanaswari Ramaswamy; Donn C Young; Amy K Ferketich; Tammy A Lamb; Michael R Grever; Charles L Shapiro; William E Carson
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

7.  Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors.

Authors:  Yenan T Bryceson; Hans-Gustaf Ljunggren; Eric O Long
Journal:  Blood       Date:  2009-07-23       Impact factor: 22.113

8.  TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells.

Authors:  Rossana Trotta; Jessica Dal Col; Jianhua Yu; David Ciarlariello; Brittany Thomas; Xiaoli Zhang; Jeffrey Allard; Min Wei; Hsiaoyin Mao; John C Byrd; Danilo Perrotti; Michael A Caligiuri
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 9.  Fc gamma receptors in respiratory syncytial virus infections: implications for innate immunity.

Authors:  Jop Jans; Marloes Vissers; Jacco G M Heldens; Marien I de Jonge; Ofer Levy; Gerben Ferwerda
Journal:  Rev Med Virol       Date:  2013-11-14       Impact factor: 6.989

10.  CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis.

Authors:  Yahui Grace Chiu; Tianmeng Shao; Changyong Feng; Kofi A Mensah; Michael Thullen; Edward M Schwarz; Christopher T Ritchlin
Journal:  Arthritis Res Ther       Date:  2010-01-26       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.